What is BridgeBio Pharma's AOCI?

BridgeBio Pharma (BBIO) reported AOCI of -$8K in Q1 2026.

What is the long-term trend for BridgeBio Pharma's AOCI?

Over 5 years (2020 to 2025), BridgeBio Pharma's AOCI has grown at a -42.6% compound annual growth rate (CAGR), from $192K to $12K.

Cumulative gains or losses that have not yet been realized through actual transactions.

How do you interpret AOCI?

Significant fluctuations can indicate exposure to market volatility, interest rate changes, or foreign exchange risk.

How does AOCI compare across companies?

Varies based on the company's international footprint and hedging activities.

BridgeBio Pharma BBIO AOCI

AOCI at other companies

PfizerPFE

-$7.2B+16.1%

Ionis PharmaceuticalsIONS

-$31.02M-7.2%

BioMarin PharmaceuticalsBMRN

-$4.24M-122%

Revolution Medicines, Inc.RVMD

-$622K-136%

Roivant SciencesROIV

$4.36M-53.8%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's AOCI?: BridgeBio Pharma (BBIO) reported AOCI of -$8K in Q1 2026.
What is the long-term trend for BridgeBio Pharma's AOCI?: Over 5 years (2020 to 2025), BridgeBio Pharma's AOCI has grown at a -42.6% compound annual growth rate (CAGR), from $192K to $12K.
What does AOCI mean?: Cumulative gains or losses that have not yet been realized through actual transactions.
How do you interpret AOCI?: Significant fluctuations can indicate exposure to market volatility, interest rate changes, or foreign exchange risk.
How does AOCI compare across companies?: Varies based on the company's international footprint and hedging activities.